Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-type-2-diabetes-us-drug-forecast-and-market-analysis-to-2022-market-report.html .
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.
